IL2 and lung carcinoma: F16-IL2 (TELEUKIN®), an IL-2 coupled antibody-cytokine fusion protein is the most advanced candidate with two clinical trials in solid tumours, such as breast and lung cancer (NCT01131364, NCT01134250).